Cucuianu A, Petrov L, Ghiurt A, Vasilache A
Oncological Institute, Malignant Hemopathies Department, Cluj-Napoca, Romania.
Rom J Intern Med. 1996 Jan-Jun;34(1-2):97-103.
Recombinant human granulocyte macrophage colony stimulating factor (GM-CSF) was given for 2-6 days in 10 patients with febrile neutropenias following remission induction chemotherapy for acute leukemia (6 acute lymphoblastic and 4 acute myeloid leukemias) in which, broad spectrum and targeted antibiotherapy was ineffective. In 7 patients, the addition of GM-CSF helped overcome the serious infectious complications, leading to an accelerated neutrophil recovery averaging 18.4 days, significantly faster than in a historic group of 9 similar patients in whom GM-CSF was not given Side-effects of GM-CSF treatment were minor and reversible. GM-CSF treatment did not have any significant effect on the achievement of complete remission status.
重组人粒细胞巨噬细胞集落刺激因子（GM-CSF）应用于10例急性白血病（6例急性淋巴细胞白血病和4例急性髓细胞白血病）缓解诱导化疗后出现发热性中性粒细胞减少症的患者，用药2至6天，这些患者在接受广谱和靶向抗微生物治疗均无效。7例患者加用GM-CSF有助于克服严重的感染并发症，使中性粒细胞恢复加快，平均为18.4天，明显快于未使用GM-CSF的9例类似历史对照患者。GM-CSF治疗的副作用轻微且可逆。GM-CSF治疗对完全缓解状态的实现没有任何显著影响。
